-
EP1660090
European procedure
Extract from the Register of European Patents
EP About this file: EP1660090
| EP1660090 - QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 27.09.2013 Database last updated on 19.07.2024 | Most recent event Tooltip | 27.09.2013 | No opposition filed within time limit | published on 30.10.2013 [2013/44] | Applicant(s) | For all designated states Array Biopharma, Inc. 3200 Walnut Street Boulder, CO 80301 / US | [2006/22] | Inventor(s) | 01 /
WALLACE, Eli 204 Cobblestone Court Lyons, CO 80540 / US | 02 /
TOPALOV, George 1697 Relience Circle Superior, CO 80027 / US | 03 /
LYSSIKATOS, Joseph 1720 Eldorado Circle Superior, CO 80027 / US | 04 /
BUCKMELTER, Alexandre 2081 Dailey Lane Superior, CO 80027 / US | 05 /
ZHAO, Qian 3919 Torrey's Peak Drive Superior, CO 80027 / US | [2006/22] | Representative(s) | Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | [N/P] |
| Former [2012/47] | Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | ||
| Former [2009/45] | Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | ||
| Former [2006/22] | Gillard, Richard Edward Elkington and Fife LLP, Prospect House 8 Pembroke Road Sevenoaks Kent TN13 1XR / GB | Application number, filing date | 04780990.0 | 10.08.2004 | [2006/22] | WO2004US26235 | Priority number, date | US20030642440 | 14.08.2003 Original published format: US 642440 | US20040551718P | 10.03.2004 Original published format: US 551718 P | [2006/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2005016346 | Date: | 24.02.2005 | Language: | EN | [2005/08] | Type: | A1 Application with search report | No.: | EP1660090 | Date: | 31.05.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.02.2005 takes the place of the publication of the European patent application. | [2006/22] | Type: | B1 Patent specification | No.: | EP1660090 | Date: | 21.11.2012 | Language: | EN | [2012/47] | Search report(s) | International search report - published on: | US | 24.02.2005 | (Supplementary) European search report - dispatched on: | EP | 31.10.2008 | Classification | IPC: | A61K31/51, A61K31/517, A61K31/535, C07D403/00, C07D239/82 | [2006/22] | CPC: |
C07D239/94 (EP,KR,US);
C07D417/14 (EP,CN,KR,US);
A61K31/517 (KR);
A61P29/00 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
C04B35/632 (EP,KR,US);
C07D401/12 (EP,KR,US);
C07D413/12 (EP,KR,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/22] | Extension states | AL | 01.03.2006 | LT | 01.03.2006 | LV | 01.03.2006 | MK | 01.03.2006 | Title | German: | CHINAZOLIN-ANALOGA ALS REZEPTOR TYROSINKINASE-HEMMER | [2006/22] | English: | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | [2006/22] | French: | ANALOGUES DE QUINAZOLINE COMME INHIBITEURS DU RECEPTEUR DE LA TYROSINE KINASE | [2006/22] | Entry into regional phase | 01.03.2006 | National basic fee paid | 01.03.2006 | Search fee paid | 01.03.2006 | Designation fee(s) paid | 01.03.2006 | Examination fee paid | Examination procedure | 28.02.2006 | Amendment by applicant (claims and/or description) | 01.03.2006 | Examination requested [2006/22] | 02.03.2009 | Despatch of a communication from the examining division (Time limit: M06) | 14.09.2009 | Reply to a communication from the examining division | 15.07.2011 | Despatch of a communication from the examining division (Time limit: M06) | 25.01.2012 | Reply to a communication from the examining division | 09.02.2012 | Despatch of a communication from the examining division (Time limit: M04) | 17.05.2012 | Reply to a communication from the examining division | 23.07.2012 | Communication of intention to grant the patent | 03.10.2012 | Fee for grant paid | 03.10.2012 | Fee for publishing/printing paid | Divisional application(s) | EP11158158.3 / EP2377539 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.03.2009 | Opposition(s) | 22.08.2013 | No opposition filed within time limit [2013/44] | Fees paid | Renewal fee | 01.03.2006 | Renewal fee patent year 03 | 29.08.2007 | Renewal fee patent year 04 | 25.08.2008 | Renewal fee patent year 05 | 25.08.2009 | Renewal fee patent year 06 | 25.08.2010 | Renewal fee patent year 07 | 25.08.2011 | Renewal fee patent year 08 | 27.08.2012 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO9730034 (ZENECA LTD [GB]) [X] 1-25 * page 4, line 15 - line 26 * * page 46; example 14 * * claim 1 *; | [Y]WO0198277 (PFIZER PROD INC [US], et al) [Y] 1-25 * page 1, line 8 - page 2, line 20 * * page 29 - page 72; examples 1-384 * * claim 1 *; | [Y]WO0202552 (GLAXO GROUP LTD [GB], et al) [Y] 1-25 * page 1, line 5 - line 10 * * page 33 - page 47; examples 1-15 ** claim 1 * | International search | [A]US5112817 (FUKAZAWA NOBUYUKI [JP], et al); | [A]US5204348 (FUKAZAWA NOBUYUKI [US], et al); | [A]US5405843 (FUKAZAWA NOBUYUKI [JP], et al); | [A]US5821246 (BROWN DEARG SUTHERLAND [GB], et al); | [A]US6127374 (BRIDGES ALEXANDER JAMES [US]) | by applicant | WO9730034 | - RIESE; STEM, BIOESSAYS, (1998), vol. 20, pages 41 - 48 | - OLAYIOYE ET AL., EMBO JOURNAL, (2000), vol. 19, pages 3159 - 3167 | - SCHLESSINGER, CELL, (2002), vol. 110, pages 669 - 672 | - SALOMON ET AL., CRIT. REV. ONCOL. HEMATOL., (1995), vol. 19, pages 183 - 232 | - KLAPPER ET AL., ADV. CANCER RES., (2000), vol. 77, pages 25 - 79 | - HYNES; STEM, BIOCHIM. BIOPHYS. ACTA, (1994), vol. 1198, pages 165 - 184 | - MENDELSOHN; BASELGA, ONCOGENE, (2000), vol. 19, pages 6550 - 6565 | - NORMANNO ET AL., ENDOCRINE-RELATED CANCER, (2003), vol. 10, pages 1 - 21 | - K. WIDDER, ET AL., Methods in Enzymology, ACADEMIC PRESS, (1985), vol. 42, pages 309 - 396 | - "A Textbook ofdrug Design and Development", H. BUNDGAARD, Design and Application of Prodrugs, (1991), pages 113 - 191 | - H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, (1992), vol. 8, pages 1 - 38 | - H. BUNDGAARD ET AL., JOURNAL OFPHARMACEUTICAL SCIENCES, (1988), vol. 77, page 285 | - N. KAKEYA ET AL., CHEM. PHARM. BULL., (1984), vol. 32, page 692 | - "Chapter 25.2", Comprehensive Medicinal Chemistry, PERGAMON PRESS, (1990), vol. 5 | - BOURRAIN ET AL., BIOORG. MED. CHEM. LETT., (1999), vol. 9, no. 23, pages 3369 - 3374 | - JACS, (1990), vol. 112, no. 13, page 5285 |